New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg;   - capsule - 500 mg - active: cefalexin monohydrate 525.8mg equivalent to cephalexin 500 mg   excipient: gelatin   magnesium stearate microcrystalline cellulose titanium dioxide   water  

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - cefalexin, quantity: 500 mg - capsule - excipient ingredients: gelatin; titanium dioxide; patent blue v; sodium lauryl sulfate; magnesium stearate; microcrystalline cellulose; sunset yellow fcf; quinoline yellow; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; ethanol absolute - respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin generichealth capsules are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin capsules in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin sensitive only). otitis media. due to s. pneumoniae, staphylococci. skin and soft tissue infections caused by staphylococci and/or streptococci. genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin generichealth capsules in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin generichealth capsules are not indicated in these conditions. note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin generichealth capsule. renal function studies should be performed when indicated.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

kela sa-nv - cefalexin monohydrate 52,6 mg - eq. cefalexin 50 mg - tablet - 50 mg - cefalexin monohydrate 52.6 mg - cefalexin - dog

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 550 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; sunset yellow fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections; strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and noumed cephalexin is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to noumed cephalexin. renal function studies should be perfomed when indicated.

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - capsule - each capsule contains cefalexin monohydrate equiv. to cefalexin 250,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - capsule - each capsule contains cefalexin monohydrate equiv. to cefalexin 500,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - tablet - each tablet contains cefalexin monohydrate equivalent to cefalexin 250,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - tablet - each tablet contains cefalexin monohydrate equivalent to cefalexin 500,0 mg

Namibia - English - Namibia Medicines Regulatory Council

aurobindo pharma (pty) ltd - cefalexin monohydrate - tablet - each tablet contains cefalexin monohydrate equivalent to cefalexin 1000,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefalexin monohydrate, quantity: 262.94 mg (equivalent: cefalexin, qty 250 mg) - capsule - excipient ingredients: colloidal anhydrous silica; magnesium stearate; lactose; titanium dioxide; brilliant blue fcf; purified water; quinoline yellow; allura red ac; gelatin; sodium lauryl sulfate - cephalexin is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms:,- respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.),- bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only),- otitis media due to s. pneumoniae, staphylococci,- skin and soft-tissue infections caused by staphylococci and/or streptococci,- genitourinary tract infections, including acute prostatitis caused by e. coli, p. mirabilis, and klebsiella sp.,the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions.,note: appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.